FDAsafety guidance77% confidence
FDA AP — CEFEPIME IN PLASTIC CONTAINER (SUPPL)
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Hikma; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Application NDA050817. Sponsor: BAXTER HLTHCARE. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: CEFEPIME HYDROCHLORIDE.
Supporting Context
- Therapeutic area
- Oncology · Supportive Care
- Sub-indication
- General
Related signal: Hikma's Leucovorin Calcium ANDA072736 Receives AP Status from FDA